X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Merck leverages Harpoon lead candidate HPN328 (MK-6070), which is being evaluated in Phase I/II clinical trial studies in combination with Atezolizumab for the treatment of Small-cell Lung Cancer.
Lead Product(s): MK-6070,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 11, 2024
Details:
The acquisition will expand Merck's oncology portfolio by including HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.
Lead Product(s): HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $680.0 million Upfront Cash: $680.0 million
Deal Type: Acquisition January 08, 2024
Details:
The Company intends to use the proceeds to fund its clinical development programs from its platforms, including ongoing as well as future late-stage clinical studies of HPN328, a TriTAC that binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities.
Lead Product(s): HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Soleus Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 23, 2023
Details:
HPN328, is a DLL3 targeting TriTAC®, which is investigated in combination with atezolizumab for the treatment of patients with small cell lung cancer.
Lead Product(s): HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
Under the agreement, AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA.
Lead Product(s): HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 13, 2023
Details:
HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells and investigated for Relapsed/Refractory Multiple Myeloma.
Lead Product(s): HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
The proceeds will be used to complete ongoing Phase 1 clinical studies for TriTAC® T cell engagers, including HPN217 (BCMA) in Phase 1 for patients with relapsed and refractory multiple myeloma, and HPN328 (DLL3), in Phase 1/2 for patients with multiple neuroendocrine tumors.
Lead Product(s): HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: New Leaf
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 27, 2023
Details:
The updated interim results from the Phase 1 trial establish clinical proof of concept of HPN217 in heavily pretreated relapsed/refractory multiple myeloma and provide further clinical validation of our proprietary TriTAC T cell engager platform.
Lead Product(s): HPN217
Therapeutic Area: Oncology Product Name: HPN217
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
HPN328, a Tri-specific T cell Activating Construct (TriTAC®), is being evaluated as monotherapy in an ongoing open-label, multicenter two-part study to assess the safety, tolerability and pharmacokinetics in patients with advanced cancers associated with expression of DLL3.
Lead Product(s): HPN328
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Under the supply agreement with Roche as it enables us to investigate the impact of HPN328 on solid tumors in combination with atezolizumab and provide further insight into the capabilities of our TriTAC technology platform.
Lead Product(s): HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
